Terms: = Endocrine gland cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Diagnosis
88 results:
1. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
2. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
3. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract] [Full Text] [Related]
4. AUM302, a novel triple kinase PIM/PI3K/mtor inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
[TBL] [Abstract] [Full Text] [Related]
5. Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.
Wu M; Yuan H; Zou W; Xu S; Liu S; Gao Q; Guo Q; Han Y; An X
Clin Transl Oncol; 2024 Apr; 26(4):808-824. PubMed ID: 37864677
[TBL] [Abstract] [Full Text] [Related]
6. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAmtor2-mediated mtor activation.
Xu J; Quan G; Huang W; Jiang J
Cell Commun Signal; 2023 Aug; 21(1):223. PubMed ID: 37626304
[TBL] [Abstract] [Full Text] [Related]
7. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio N; La Salvia A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
[TBL] [Abstract] [Full Text] [Related]
8. UQCRFS1 serves as a prognostic biomarker and promotes the progression of ovarian cancer.
Sun Q; Li J; Dong H; Zhan J; Xiong X; Ding J; Li Y; He L; Wang J
Sci Rep; 2023 May; 13(1):8335. PubMed ID: 37221238
[TBL] [Abstract] [Full Text] [Related]
9. In-depth proteomic signature of parathyroid carcinoma.
Kong SH; Lee JH; Bae JM; Hong N; Kim H; Park SY; Choi YJ; Lee S; Rhee Y; Kim SW; Han D; Kim JH; Shin CS
Eur J Endocrinol; 2023 Apr; 188(4):385-394. PubMed ID: 36995894
[TBL] [Abstract] [Full Text] [Related]
10. Approach to the Patient With Prolactinoma.
Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
[TBL] [Abstract] [Full Text] [Related]
11. Hypoxia-induced miR-9 expression promotes ovarian cancer progression via activating PI3K/AKT/mtor/GSK3β signaling pathway.
Zhu WJ; Huang HH; Feng YF; Zhan L; Yang J; Zhu L; Wang QY; Wei B; Wang WY
Neoplasma; 2023 Apr; 70(2):216-228. PubMed ID: 36964721
[TBL] [Abstract] [Full Text] [Related]
12. Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K/AKT/mtor pathway.
Chen J; Liu F; Wu J; Yang Y; He J; Wu F; Yang K; Li J; Jiang Z; Jiang Z
Cell Signal; 2023 Jun; 106():110642. PubMed ID: 36871796
[TBL] [Abstract] [Full Text] [Related]
13. Advances in Ovarian cancer Treatment Beyond PARP Inhibitors.
Aliyuda F; Moschetta M; Ghose A; Sofia Rallis K; Sheriff M; Sanchez E; Rassy E; Boussios S
Curr Cancer Drug Targets; 2023; 23(6):433-446. PubMed ID: 36757037
[TBL] [Abstract] [Full Text] [Related]
14. Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X; Xu T; Lin X; Xu S; Fan Y; Guo B; Deng X; Jiao Q; Chen L; Wei Z; Chen C; Yang W; Zhang Z; Yu X; Yue H
J Clin Endocrinol Metab; 2023 Jun; 108(7):1768-1775. PubMed ID: 36611251
[TBL] [Abstract] [Full Text] [Related]
15. Validation of ESM1 Related to Ovarian cancer and the Biological Function and Prognostic Significance.
Li YK; Zeng T; Guan Y; Liu J; Liao NC; Wang MJ; Chen KX; Luo XY; Chen CY; Quan FF; Wang J; Zhang QF; Zou J
Int J Biol Sci; 2023; 19(1):258-280. PubMed ID: 36594088
[No Abstract] [Full Text] [Related]
16. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
Farah AM; Gu S; Jia Y
Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
[TBL] [Abstract] [Full Text] [Related]
17. Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mtor Signaling Pathway.
Luo X; Wang J; Lu J; Wang X; Miao Y; Li Q; Li X; Wang L
Biomed Res Int; 2022; 2022():1874550. PubMed ID: 35757470
[TBL] [Abstract] [Full Text] [Related]
18. Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes.
Evans LM; Geenen KR; O'Shea A; Hedgire SS; Ferrone CR; Thiele EA
Am J Med Genet A; 2022 Sep; 188(9):2666-2671. PubMed ID: 35612824
[TBL] [Abstract] [Full Text] [Related]
19. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
20. Genetics and Epigenetics of Parathyroid Carcinoma.
Marini F; Giusti F; Palmini G; Perigli G; Santoro R; Brandi ML
Front Endocrinol (Lausanne); 2022; 13():834362. PubMed ID: 35282432
[TBL] [Abstract] [Full Text] [Related]
[Next]
